Skip to main content

Table 4 Univariate predictors of 30 day mortality in patients with CAL and HAL.a

From: Clinical features and predictors of mortality in admitted patients with community- and hospital-acquired legionellosis: A Danish historical cohort study

  CAL   HAL b  
Predictor variables by category Odds ratio (95% CI) P-value Odds ratio (95% CI) P-value
Variables known at the time of patient presentation     
Demographics     
Age > 65 years 3.9 (1.9-8.1) <0.001* 0.7 (0.2-2.0) 0.46
Case associated with travelling to another country 0.4 (0.1-0.9) 0.03* x x
Comorbid illnesses     
Any comorbidityc 2.4 (1.1-4.9) 0.02* 2.2 (0.2-21.5) 0.49
Immunosuppression 6.3 (2.7-14.8) <0.001* 1.5 (0.5-4.6) 0.48
Malignancy 4.7 (1.6-13.9) 0.005* 2.1 (0.7-6.9) 0.20
Renal insufficiency 7.2 (1.4-37.1) 0.02 0.4 (0.04-3.4) 0.38
Charlson Comorbidity Index ≥ 2 3.7 (1.7-8.3) 0.001* 1.5 (0.5-4.6) 0.48
Current smoker 0.5 (0.2-1.1) 0.09 0.4 (0.1-1.6) 0.21
Symptoms     
Self-reported fever 0.4 (0.2-0.9) 0.03* 2.1 (0.7-6.6) 0.21
Dyspnoea 2.4 (1.1-5.1) 0.03* 0.6 (0.2-1.9) 0.42
Headache 0.1 (0.01-0.5) 0.01* 0.4 (0.05-4.3) 0.49
Confusion 1.9 (0.9-4.2) 0.01* 0.3 (0.03-2.5) 0.26
Signs     
Normal pulmonary stethoscopy 0.2 (0.1-1.02) 0.05 1.6 (0.3-8.4) 0.56
Laboratory tests     
Lymphocytosis, lymphocyte count >3.5 cells 109/L 6.7 (0.9-49.6) 0.06 2.6 (0.1-45.4) 0.52
Bilirubin >23 mikromol/L 8.3 (2.9-24.1) <0.001* 1.0 (0.3-4.1) 0.96
Creatinine >115 mikromol/L 2.5 (1.2-5.2) 0.01* 0.7 (0.2-2.6) 0.57
Blood urea nitrogen >7.5 mmol/L 4.2 (1.3-13.3) 0.02* 0.9 (1.1-5.6) 0.89
Hyponatremia, sodium <128 mmol/L 0.3 (0.1-1.0) 0.049* 0.6 (0.1-2.6) 0.49
Hypercapnia, PaCO2 >6 kPa 4.4 (0.97-19.9) 0.06 1.6 (0.3-10.1) 0.60
Atrial fibrillation at admission 2.6 (1.01-6.9) 0.048* 1.2 (0.3-5.1) 0.77
X-ray findings     
Unilateral infiltrate on chest x-ray 0.8 (0.4-1.6) 0.46 0.4 (0.1-1.2) 0.09
Severity of illness     
PSI risk class >2 9.1 (2.1-38.7) <0.01* 2.2 (0.7-2.7) 0.20
CURB65 risk class >2 3.6 (1.0-12.8) 0.045* 0.6 (0.1-6.3) 0.68
Variables known later during admission     
Treatment for legionellosis     
Treatment with anti-legionella antibiotics     
<24 hours from baselined 1 (ref.)   1 (ref.)  
>24 hours from baselined 3.6 (0.8-15.6) 0.09 0.4 (0.1-2.0) 0.24
No treatment with anti-legionella antibiotics during admission 11.5 (2.1-64.3) <0.01* 6.0 (0.4-85.2) 0.19
  1. a For community-acquired cases 30 days from admission. For hospital-acquired cases 30 days from onset of symptoms
  2. b A case was defined as hospital-acquired if the patient had been admitted within the preceding 10 days or if the patient developed
  3. symptoms of legionellosis more than 2 days after hospital admission.
  4. c Immunosuppression, malignancy, chronic obstructive pulmonary disease, ischaemic heart disease, congestive heart failure, diabetes mellitus
  5. or renal insufficiency.
  6. d For community-acquired cases time from admission. For hospital-acquired cases time from beginning of symptoms.
  7. * P-level < 0.05 is considered statistically significant